Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc., as indicated in the metadata) regarding events occurring on January 1, 2016. The filing details the execution of new employment agreements with the Company's Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- CEO Base Salary: $470,000 per year.
- CFO Base Salary: $357,500 per year.
- CEO Stock Options: 800,000 non-qualified options at $5.18/share (350,000 vested immediately; remainder vests over 48 months).
- CFO Stock Options: 150,000 non-qualified options at $5.18/share (vests over 48 months).
- Performance Bonus: Up to 50% of base salary for both executives based on performance objectives.
Material Changes
The primary material change is the formalization of long-term employment terms for top executives effective January 1, 2016, extending through January 1, 2020, with automatic one-year renewals. This establishes specific severance and change-of-control provisions not previously detailed in this filing.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. Key contingencies and risks related to the agreements include:
- Termination without Cause/Good Reason: CEO receives 24 months of base salary; CFO receives 12 months of base salary.
- Change of Control: Both executives receive 24 months of base salary (CEO) or 12 months (CFO) plus immediate vesting of all unvested options, exercisable for six months.
- Voluntary Termination/For Cause: Executives receive only unpaid compensation, earned bonuses, and expenses incurred prior to termination.
Important Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 950,000 new options granted.
- Confirm the specific performance criteria required to achieve the 50% cash bonus.
- Review the full employment agreements attached to the Form 10-K for the year ended December 31, 2015, for complete legal terms.
- Note the discrepancy between the metadata company name (Cardiff Oncology) and the filing registrant (Trovagene).